Gepirone Under Review for Major Depressive Disorder
Exxua (previously named Travivo) is a novel oral serotonin 1A receptor agonist.
All articles by Steve Duffy
Best Diets According to the Experts: 2023 Rankings Revealed
A 33 person panel of physicians, registered dietitian nutritionists, and nutritional epidemiologists assessed 24 diets to come up with the final results.
Investigational Therapy Gets Fast Track Status for Glioblastoma Multiforme
In preclinical studies, WP1122 has shown to increase cellular uptake of 2-DG, increase drug half-life, and increase the ability to cross the blood brain barrier.
Sezaby Approved to Treat Seizures in Term and Preterm Infants
The FDA has approved Sezaby (phenobarbital sodium powder for injection) for the treatment of neonatal seizures in term and preterm infants.
Monarch eTNS, a Bioelectronic Medical Device for Pediatric ADHD, Now Available
The device gained FDA approval in 2019 based on data from a placebo-controlled clinical trial that included 62 children with moderate to severe ADHD.
DEA: “Rainbow Fentanyl” a Deliberate Tactic to Target Young People
Brightly colored versions of the synthetic opioid fentanyl are appearing across the US, according to the Drug Enforcement Administration (DEA). In a press statement, the Agency reported that the colorful fentanyl, dubbed “rainbow fentanyl”, has been seized in 18 different states and has been found in multiple forms, including pills, powder, and blocks that resemble…
FDA to Review Resubmitted Application for Severe Burn Therapy NexoBrid
NexoBrid is a topically administered, bromelain-based biological product containing a sterile mixture of proteolytic enzymes.
AbbVie Seeks Crohn Disease Indication for Upadacitinib
The application is supported by data from the two phase 3 induction studies, U-EXCEED and U-EXCEL, and one phase 3 maintenance study, U-ENDURE.
Istodax Generic Equivalent Now Available
Romidepsin is a histone deacetylase inhibitor indicated for the treatment of cutaneous T-cell lymphoma.
FDA Extends Review Period for Teplizumab for Type 1 Diabetes Delay
Teplizumab is an investigational anti-CD3 monoclonal antibody that has been shown to preserve beta cell function, reducing the need for exogenous insulin.
- Loading...
Loading...
Next post in Endocrinology
Loading... 
Loading...